Annexon Biosciences is pioneering the development of first-in-class therapeutic products that halt the progression of complement-mediated neurodegeneration (CMND). Backed by a team of experts in CMND, Annexon's mission is to rapidly advance disease-modifying therapies for patients with acute and chronic neurodegenerative disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/23/16 | $44,000,000 | Series B |
Clarus Ventures Correlation Ventures Novartis Venture Funds Satter Investment Management | undisclosed |
| 12/19/18 | $75,000,000 | Series C |
Adage Capital Management Bain Capital  Blackstone New Enterprise Associates Novartis Venture Funds Satter Investment Management Surveyor Capital | undisclosed |
| 07/02/20 | $100,000,000 | Venture |
Adage Capital Partners Bain Capital Life Sciences BlackRock Deerfield Management Company, L.P. Eventide Asset Management Farallon Capital Management Janus Henderson Investors Logos Capital New Enterprise Associates Redmile Group Satter Medical Technology Partners Surveyor Capital | undisclosed |
